Winkler Michael
Klinik für Visceral- und Transplantationschirurgie, Transplantationschirurgie, Medizinische Hochschule Hannover, Germany.
Curr Opin Investig Drugs. 2002 Oct;3(10):1464-7.
OPi (formerly Orphan Pharma International) is developing inolimomab, an anti-interleukin-2 receptor (CD25) monoclonal antibody for the potential treatment of acute graft versus host disease. As of April 2001, inolimomab was undergoing phase II/III clinical trials.
OPi（前身为孤儿药国际公司）正在研发inolimomab，一种抗白细胞介素-2受体（CD25）单克隆抗体，用于潜在治疗急性移植物抗宿主病。截至2001年4月，inolimomab正在进行II/III期临床试验。
